Metaplastik Meme Tümörü: Klinik Özellikler, Tanı ve Tedavi Yaklaşımları
Özet
Metaplastik meme tümörü olarak bilinen metaplastik meme karsinomu, nadir görülen ve agresif bir meme kanseri türüdür. Hem epitelial hem de mezenkimal bileşenler içeren heterojen histolojik yapısı nedeniyle tanı ve tedavisi zordur. Genellikle 36-50 yaş arasındaki kadınlarda görülür ve tipik olarak hızlı büyür. Tanı, görüntüleme yöntemleri ve histopatolojik incelemelerle konulurken, tedavi cerrahi, radyoterapi, kemoterapi ve immünoterapiden oluşur. Erken tanı ve uygun tedavi, hastaların prognozunu iyileştirme açısından büyük önem taşır. Metaplastik meme karsinomu, genellikle kemoterapiye duyarlı olmasına rağmen, daha düşük kemosensitiviteye sahiptir ve prognozu genellikle kötüdür.
Referanslar
Thomas HR, Hu B, Boyraz B, Johnson A, Bossuyt VI, Spring L, et al. Metaplastic breast cancer: A review. Crit Rev Oncol Hematol. 2023;182:103924.
Fayaz S, Demian GA, Eissa HE, Amanguno H, Abuzalouf S. Metaplastic breast carcinoma: Analysis of 31 cases from a single institute. J Egypt Natl Canc Inst. 2017;29(3):141-5.
Khong K, Zhang Y, Tomic M, Lindfors K, Aminololama-Shakeri S. Aggressive Metaplastic Carcinoma of the Breast with Osteoclastic Giant Cells. J Radiol Case Rep. 2015;9(9):11-9.
Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020;22(1):121.
Lai YC, Hsu CY, Chou YH, Tiu CM, Tseng LM, Wang HK, et al. Sonographic presentations of metaplastic breast cancers. J Chin Med Assoc. 2012;75(11):589-94.
Haroon S, Zia S, Shirazi UA, Ahmed O, Asghar IA, Diwan MA, et al. Metaplastic Breast Carcinoma: Clinicopathological Parameters and Prognostic Profile. Cureus. 2021;13(4):e14347.
Takatsuka D, Ogura H, Asano Y, Nakamura A, Koizumi K, Shiiya N, et al. A difficult-to-diagnose fibromatosis-like metaplastic carcinoma of the breast: a case report. Surg Case Rep. 2021;7(1):16.
Tang J, Zhang D, Pan X. Development and validation of competitive risk model for older women with metaplastic breast cancer. BMC Womens Health. 2023;23(1):374.
Meng HM, Yang YF, Qi LQ, Gu L. [Clinical characteristics and survival analysis of 22 cases of pure epithelial breast metaplastic carcinoma]. Zhonghua Zhong Liu Za Zhi. 2013;35(7):525-9.
Hasbay B, Bolat FA, Aytac HO, Aslan H, Purbager A. Metaplastic Carcinoma of the Breast: Analysis of 38 Cases from a Single Institute. Turk Patoloji Derg. 2020;36(1):23-30.
Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011;126(2):471-8.
Patterson SK, Tworek JA, Roubidoux MA, Helvie MA, Oberman HA. Metaplastic carcinoma of the breast: mammographic appearance with pathologic correlation. AJR Am J Roentgenol. 1997;169(3):709-12.
Donato H, Candelaria I, Oliveira P, Goncalo M, Caseiro-Alves F. Imaging Findings of Metaplastic Carcinoma of the Breast with Pathologic Correlation. J Belg Soc Radiol. 2018;102(1):46.
Velasco M, Santamaria G, Ganau S, Farrus B, Zanon G, Romagosa C, et al. MRI of metaplastic carcinoma of the breast. AJR Am J Roentgenol. 2005;184(4):1274-8.
Sae-Kho TM, Bhatt A, Solanki MH, Jeans EB, Corbin KS, Fazzio RT, et al. Imaging features of adenosquamous carcinoma of the breast - A rare variant of metaplastic breast carcinoma. BJR Case Rep. 2022;7(6):20210108.
Asare B, White MJ, Rossi J. Metaplastic carcinoma with osteosarcomatous differentiation in the breast: Case report. Radiol Case Rep. 2023;18(12):4272-80.
Drekolias D, Mamounas EP. Metaplastic breast carcinoma: Current therapeutic approaches and novel targeted therapies. Breast J. 2019;25(6):1192-7.
McMullen ER, Zoumberos NA, Kleer CG. Metaplastic Breast Carcinoma: Update on Histopathology and Molecular Alterations. Arch Pathol Lab Med. 2019;143(12):1492-6.
Ullah A, Khan J, Yasinzai AQK, Tracy K, Nguyen T, Tareen B, et al. Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape. Cancers (Basel). 2023;15(11).
Puskulluoglu M, Konieczna A, Swiderska K, Streb J, Pieniazek M, Grela-Wojewoda A, et al. Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study. Acta Oncol. 2024;63:620-35.
Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, et al. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Rep Oncol Med. 2020;2020:2518383.
Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, et al. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022;28(13):2878-89.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386(6):556-67.
Joneja U, Vranic S, Swensen J, Feldman R, Chen W, Kimbrough J, et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol. 2017;70(3):255-9.
